SCHEMBL22988253

SCHEMBL22988253

Cc1cccc2c1nc(N[C@@H]1CNCCNC1=O)n1nc(-c3cnn(C)c3)nc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 7/20 0.35
ADORA2A P29274 7/20 0.35
ADORA1 P30542 7/20 0.35
ADORA2B P29275 5/20 0.35
CHEK1 O14757 7/20 0.33
IRAK4 Q9NWZ3 3/20 0.33
RPLP1 P05386 1/20 0.33
RPLP0 P05388 1/20 0.33
RPS17 P08708 1/20 0.33
RPSA P08865 1/20 0.33
RPS2 P15880 1/20 0.33
RPL35A P18077 1/20 0.33
RPL7 P18124 1/20 0.33
RPL17 P18621 1/20 0.33
RPS4Y1 P22090 1/20 0.33
RPS3 P23396 1/20 0.33
RPS12 P25398 1/20 0.33
RPL13 P26373 1/20 0.33
RPL10 P27635 1/20 0.33
RPL12 P30050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22987891 0.91 RPLP1 (0.34) ADORA3ADORA2AADORA1ADORA2BCHEK1
SCHEMBL29645541 0.91 IRAK4 (0.34) ADORA3ADORA2AADORA1ADORA2BCHEK1
SCHEMBL22987861 0.91 ADORA3 (0.34) ADORA3ADORA2AADORA1ADORA2BCHEK1
SCHEMBL22988299 0.91 ADORA3 (0.34) ADORA3ADORA2AADORA1ADORA2BCHEK1
SCHEMBL22978977 0.91 IRAK4 (0.34) ADORA3ADORA2AADORA1ADORA2BCHEK1
SCHEMBL22988396 0.90 CCNK (0.38) ADORA3ADORA2AADORA1ADORA2BCHEK1
SCHEMBL29645793 0.90 CCNK (0.38) ADORA3ADORA2AADORA1ADORA2BCHEK1
SCHEMBL22979421 0.89 ADORA3 (0.33) ADORA3ADORA2AADORA1ADORA2BCHEK1
SCHEMBL22988494 0.89 CHEK1 (0.34) ADORA3ADORA2AADORA1ADORA2BCHEK1
SCHEMBL29645422 0.89 CHEK1 (0.34) ADORA3ADORA2AADORA1ADORA2BCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP claimed
CN-114466850-A [1,2,4] triazolo [1,5-C ] quinazolin-5-amines 拜耳股份有限公司 2022-05-10 CN claimed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 ADORA3 34/4885ADORA2A 103/4885ADORA1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.